Goldstein, N., McLean, C., Gaddah, A., Doua, J., Keshinro, B., Bus-Jacobs, L., . . . Douoguih, M. (2024). Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial. Human vaccines & immunotherapeutics, 20(1), 2327747. https://doi.org/10.1080/21645515.2024.2327747
Citácia podle Chicago (17th ed.)Goldstein, Neil, et al. "Lot-to-lot Consistency, Immunogenicity, and Safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola Virus Vaccine Regimen: A Phase 3, Randomized, Double-blind, Placebo-controlled Trial." Human Vaccines & Immunotherapeutics 20, no. 1 (2024): 2327747. https://doi.org/10.1080/21645515.2024.2327747.
Citácia podľa MLA (8th ed.)Goldstein, Neil, et al. "Lot-to-lot Consistency, Immunogenicity, and Safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola Virus Vaccine Regimen: A Phase 3, Randomized, Double-blind, Placebo-controlled Trial." Human Vaccines & Immunotherapeutics, vol. 20, no. 1, 2024, p. 2327747, https://doi.org/10.1080/21645515.2024.2327747.